275 WYMAN STREET, WALTHAM, MA
Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences Files Prospectus Supplement for $400M Common Stock Offering
2026 Annual Meeting Results; Directors Elected at Cogent Biosciences
Reports Recent Business Highlights and First Quarter 2026 Financial Results
Annual Report to Security Holders
Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Other Events
Cogent Biosciences Completes $230 Million Convertible Notes Offering
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus